Compounds > carbon tetrachloride
Page last updated: 2024-08-17

carbon tetrachloride and sc 236

carbon tetrachloride has been researched along with sc 236 in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (33.33)18.2507
2000's2 (66.67)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Altuna, R; Arroyo, V; Bosch-Marcè, M; Clària, J; Jiménez, W; Masferrer, JL; Poo, JL; Rivera, F; Rodés, J; Titos, E1
Arroyo, V; Clària, J; López-Parra, M; Masferrer, JL; Miquel, R; Planagumà, A; Rodés, J; Titos, E1
Arroyo, V; Clària, J; Ferré, N; González-Périz, A; Horrillo, R; López-Parra, M; Masferrer, JL; Miquel, R; Planagumà, A; Titos, E1

Other Studies

3 other study(ies) available for carbon tetrachloride and sc 236

ArticleYear
Selective inhibition of cyclooxygenase 2 spares renal function and prostaglandin synthesis in cirrhotic rats with ascites.
    Gastroenterology, 1999, Volume: 116, Issue:5

    Topics: Animals; Ascites; Body Water; Carbon Tetrachloride; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Glomerular Filtration Rate; Hemodynamics; Isoenzymes; Ketorolac; Kidney; Kidney Function Tests; Liver Cirrhosis, Experimental; Male; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Pyrazoles; Rats; Rats, Wistar; RNA, Messenger; Sulfonamides; Tolmetin; Urine

1999
The selective cyclooxygenase-2 inhibitor SC-236 reduces liver fibrosis by mechanisms involving non-parenchymal cell apoptosis and PPARgamma activation.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2005, Volume: 19, Issue:9

    Topics: Actins; Animals; Apoptosis; Carbon Tetrachloride; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Kupffer Cells; Liver; Liver Cirrhosis, Experimental; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; PPAR gamma; Prostaglandin D2; Pyrazoles; Rats; Rats, Wistar; RNA, Messenger; Sulfonamides

2005
Comparative protection against liver inflammation and fibrosis by a selective cyclooxygenase-2 inhibitor and a nonredox-type 5-lipoxygenase inhibitor.
    The Journal of pharmacology and experimental therapeutics, 2007, Volume: 323, Issue:3

    Topics: Animals; Apoptosis; Arachidonate 5-Lipoxygenase; Carbon Tetrachloride; Cell Line; Cell Survival; Chemical and Drug Induced Liver Injury; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Drug Therapy, Combination; Gene Expression; Gene Expression Profiling; Imidazoles; In Situ Nick-End Labeling; Lipoxygenase Inhibitors; Liver Cirrhosis, Experimental; Macrophages; Male; Mice; Mice, Inbred Strains; Oxidation-Reduction; Pyrazoles; Reverse Transcriptase Polymerase Chain Reaction; Sulfides; Sulfonamides

2007